Cristian Massacesi
Onco
Daily
Twitter
Facebook
Youtube
RSS Feed
Linkedin
Facebook
RSS
Twitter
Youtube
Linkedin
July, 2024
July 2024
M
T
W
T
F
S
S
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
« Jun
Cristian Massacesi
Jun 11, 2024, 11:49 |
Blog
Cristian Massacesi: Very much enjoyed being part of the Endpoints panel at ASCO2024
Cristian Massacesi, Chief Medical Officer and Oncology Chief Development Officer at AstraZeneca, posted on LinkedIn:…
May 29, 2024, 06:28 |
Blog
Cristian Massacesi: Another memorable congress for AstraZeneca to present over 100 abstracts at ASCO 24
Cristian Massacesi, Chief Medical Officer and Oncology Chief Development Officer at AstraZeneca, posted on LinkedIn:…
Apr 25, 2024, 14:41 |
Blog
Cristian Massacesi: I’m proud to share that AstraZeneca was named one of the winners of Bio-IT World's Innovative Practices Awards at Bio-IT Expo in Boston
Cristian Massacesi, Chief Medical Officer and Oncology Chief Development Officer at AstraZeneca, posted on LinkedIn:…
Feb 14, 2024, 13:30 |
Blog
Cristian Massacesi: We must continue to push for a common baseline of opportunity in STEM and ensure that everyone is inspired by the role of STEM in our future world
Cristian Massacesi, Chief Medical Officer and Oncology Chief Development Officer at AstraZeneca, recently posted on…
Nov 2, 2023, 01:12 |
Blog
Cristian Massacesi: I never fail to be impressed by my teams’ commitment in delivering science
Cristian Massacesi, Chief Medical Officer & Oncology Chief Development Officer at AstraZeneca, made the following…
Sep 29, 2023, 18:43 |
Blog
Cristian Massacesi: Just completed another inspiring trip – this time to China and Taiwan – to meet up with AstraZeneca colleagues and connect with local clinical researchers conducting trials into potential new cancer treatments.
All:
6
Posts:
1 - 10
Eliot Levitt: The Yvonne Awards demonstrate something that it doesn't hurt to be reminded of
New data from the NEST clinical trial was presented at ESMOGI24 - Agenus
Zainab Shinkafi-Bagudu's latest commentary on Cervical Cancer Elimination Forum
New Paper Alert! Amivantamab-Lazertinib Improves Outcomes in High-Risk EGFR-Mutant NSCLC Subgroups: MARIPOSA Study Results
Learn more about overcoming barriers to immunotherapy for microsatellite stable colorectal cancer
Facebook
RSS Feed
Twitter
Linkedin
Youtube